Table 5.

Predictors of abdominal aorta Pathobiological Determinants of Atherosclerosis in Youth (PDAY) risk scores ≥ 1 versus 0 among the 165 perinatally HIV-infected children in the study population at their most recent visit.

Characteristic	Multivariable Odds Ratio (95% CI)	P
Current* HIV viral load, copies/mL		0.04
≤400	Reference
401–5,000	0.08 (0.01, 0.67)
>5,000	0.45 (0.14, 1.40)
Current*,† CDC category		0.04
N/A	Reference
B	0.30 (0.09, 1.02)
C	1.37 (0.49, 3.82)
Cumulative duration of boosted protease inhibitor use, years		<0.01
0	Reference
1–4	0.70 (0.15, 3.28)
5–8	5.85 (1.62, 21.17)
>8	3.82 (0.92, 15.78)
Current* abacavir use		0.30
Yes	1.77 (0.60, 5.27)
No	Reference
Current* lamivudine use		0.21
Yes	2.19 (0.65, 7.43)
No	Reference
Ever tenofovir disoproxil fumarate use		0.57
Yes	0.75 (0.28, 2.03)
No	Reference

^*Current defined as measurement at most recent visit.

^†A significant association was seen for current CDC category C relative to category B -multivariable odds ratio (95% CI): 4.59 (1.42, 14.78).

CDC: Centers for Disease Control and Prevention (N/A: not/mildly symptomatic, B: moderately symptomatic, C: severely symptomatic (AIDS definition)).